Source: BioPortfolio

Inotek Pharmaceuticals: Rocket Pharmaceuticals and Inotek Pharmaceuticals Complete Merger Transaction

Strong Support by Shareholders Approving Merger Proposal MultiPlatform Approach to Develop Gene Therapies for Rare Diseases Multiple Programs in the Clinic in 2018; Data from One or More Programs During the ...

Read full article »
Annual Revenue
$100K-5.0M
Employees
250-500
David P. Southwell's photo - President & CEO of Inotek Pharmaceuticals

President & CEO

David P. Southwell

CEO Approval Rating

70/100

Read more